Publications by authors named "Lotte S Spekhorst"
Article Synopsis
- The study examines the long-term effectiveness and safety of dupilumab, a treatment for atopic dermatitis (AD), in a diverse group of patients over a period of up to 5 years.
- Conducted in the Netherlands using the BioDay registry, the research includes 1,286 patients of different age groups receiving dupilumab between 2017 and 2022, with outcomes evaluated using various clinical measures.
- Results show that a majority of patients maintained controlled AD symptoms, with high levels of treatment effectiveness observed over time, and factors for treatment discontinuation were also assessed.
Article Synopsis
- A study evaluated the effectiveness and safety of dupilumab for treating moderate-to-severe atopic dermatitis (AD) over a long-term period of up to 5 years, emphasizing patient-reported outcomes.
- Data from 1223 patients (1108 adults and 115 children) showed improved quality of life measures and work impairment in both groups after at least one year of treatment.
- Despite the treatment's favorable safety profile, including a 66.8% reporting rate of adverse events (most commonly conjunctivitis), there were significant amounts of missing data in reported outcomes, particularly in children.
Article Synopsis
- The increased use of dupilumab for treating atopic dermatitis (AD) has led to reports of cutaneous T-cell lymphomas (CTCL) and related lymphoid infiltrates in patients.
- A study at the University Medical Center Utrecht analyzed adult patients with AD who were thought to have CTCL during dupilumab treatment, finding that some patients had symptoms resembling mycosis fungoides (MF), but with different histopathologic features.
- The findings suggest that while dupilumab can induce a benign lymphoid reaction that mimics CTCL, these changes are reversible and exhibit distinct histological characteristics.*
Article Synopsis
- The study examines patient-centred dosing of dupilumab for atopic dermatitis (AD), focusing on its effectiveness and cost savings in daily practice.
- A total of 595 adult patients were assessed, with 401 managing to successfully taper their dupilumab treatment after controlling their eczema symptoms for over a year.
- Successful tapering was achieved in 83.3% of cases, suggesting that reducing medication frequency is both effective for patient health and economically beneficial, with estimated savings of nearly €4 million.
Article Synopsis
- Upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treating moderate-to-severe atopic dermatitis based on clinical trials, but more studies on its real-world application are needed.
- A prospective study involving 47 patients showed that after 16 weeks of treatment, 73% achieved a significant reduction in eczema severity, and 69% reported lower itch levels.
- While the treatment worked well for patients who had not responded to other medications, about 30% of participants discontinued due to ineffectiveness or side effects, with common issues including acne, herpes, nausea, and respiratory infections.
Article Synopsis
- Clinical trials indicate that baricitinib is an effective oral treatment for moderate-to-severe atopic dermatitis, though there's limited data from everyday clinical use.
- A multicenter study assessed the treatment's effectiveness and safety over 16 weeks in 51 adults, using various outcome measurements at multiple check-ins.
- Despite some positive outcomes, a significant number of patients (43.2%) stopped treatment due to ineffectiveness or side effects, highlighting the variability in effectiveness and safety in this patient group.
Article Synopsis
- The study focuses on patients with atopic dermatitis (AD) undergoing treatment with dupilumab, aiming to investigate the relationship between serum levels of dupilumab at 16 weeks and both treatment response and adverse effects.
- Conducted at the University Medical Center Utrecht, the research involved 295 adult patients treated according to a specific clinical protocol, excluding those who changed dosage or discontinued treatment early.
- Main outcomes included assessing disease severity using the Eczema Area and Severity Index (EASI) and analyzing treatment responses, with results gathered from January to June 2022.
Article Synopsis
- Long-term data on the survival of dupilumab in patients with atopic dermatitis (AD) is limited, and there is a need to understand what factors influence its effectiveness over time.
- The study analyzed data from 715 adult patients in the Netherlands, showing that dupilumab had drug survival rates of 90.3%, 85.9%, and 78.6% at 1, 2, and 3 years, respectively.
- Factors linked to shorter drug survival included the use of immunosuppressants and being a nonresponder at 4 weeks, as well as age over 65 and severe forms of AD, indicating specific characteristics that could predict treatment outcomes.
Article Synopsis
- A study was conducted to evaluate different dosing regimens of dupilumab for patients with controlled atopic dermatitis (AD), using a patient-centered approach, as no real-world studies existed on this topic.
- Ninety adult patients were divided into three groups based on their dupilumab dosing frequency, with results showing that disease severity scores remained stable despite changes in dosing intervals.
- Although some patients experienced a temporary increase in pruritus (itching), overall biomarkers and dupilumab serum levels indicated that dose reduction could be effective while maintaining low disease activity for those with controlled AD.
Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a large multi-centre cohort of adult patients with difficult-to-treat atopic dermatitis in daily practice. Patients treated with dupilumab participating in the Dutch BioDay Registry reporting employment were included.
View Article and Find Full Text PDFBackground: Eczema control is a new construct to be measured in atopic dermatitis (AD).
Objectives: Measuring patient-perceived eczema control and treatment satisfaction in AD patients, treated with dupilumab between 16 and 52 weeks.
Methods: Cross-sectional questionnaire study.
Background: Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited.
Objective: To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis.
Methods: Patients treated with dupilumab and participating in the Dutch BioDay registry were included.